The market size of the Global Viral Vector Purification Market in the year 2021 is valued at 6.59 billion and is predicted to reach 18.37 billion by the year 2030 at a 12.4% CAGR during the forecast period.
Curious about this latest version of report? Obtain Report Details@ https://www.insightaceanalytic.com/report/global-viral-vector-purification-market-/1287
The viral vector purification market is being driven by increased demand for viral vectors. Virus vectors are extensively used by molecular biologists to convey genetic material into cells. This procedure can be performed in vivo (within a living organism) or in cell culture (in vitro). This process can be carried out either in vivo (into a living creature) or in cell culture (in vitro). Viruses have evolved unique molecular methods to convey their genomes efficiently into infected cells. The transmission of genes or other genetic material via a vector is known as transduction; transduced cells are infected cells. The emergence of COVID-19 and the increased demand for viral vaccines are driving the viral vector purification market. A lack of scalability hampers the viral vector purification market. The increasing prevalence of infectious diseases presents an opportunity for the viral vector purification market. A skilled labor shortage is a challenge for the viral vector purification market. The viral vector purification products market is currently being driven by the initially listed surge in viral vector demand. In this context, it is worth stating that several virus-based vaccines against the novel SARS-CoV-2 coronavirus strain are being developed. According to the WHO, over 20 viral vaccines are currently being tested against the novel coronavirus. Developing methods to better purify viruses is thus likely to have a significant impact on viable vaccine yield. The current crisis will undoubtedly have a significant impact on the market for virus purification products.
List of Prominent Players in the Global Viral Vector Purification Market:
Cytiva (formerly GE Lifesciences)
Thermo Fisher Scientific
The rising demand for viral vectors is driving the viral vector purification market. The increasing prevalence of target disorders and diseases and the efficacy of viral vectors in gene therapy delivery are propelling the viral vectors and virus purification products manufacturing market forward. Constant research into viral vector-based gene and cell therapies, as well as the availability of funding for gene therapy advancement, are fueling this growth. The growing number of partnerships or collaborations among the various organizations involved in this sector reflects the growing interest in vector manufacturing. These collaborations are formed for a variety of reasons. Collaborations have been signed for a variety of purposes, including the development or acquisition of manufacturing facilities, as well as the out/in-licensing of vector manufacturing technology.
Some of the factors limiting this market’s growth include “noise” during process development. This noise in cell-based assays may make evaluating process improvements difficult. The requirement for clinical-grade and thoroughly polished final products has resulted in the implementation of extremely complex procedures. Such high-tech procedures require a significant investment from viral vector companies during the initial set of production units. Moreover, stringent government regulations for approving any new development in the healthcare sector continue to be the main impediment to the rapid development of viral vectors for various purposes. In addition, the lack of adequate laboratories for testing and approval of critical raw materials is undoubtedly a limiting factor for the growth of the global viral vector development market.
North America dominated the global viral vector market in 2020, accounting for nearly half of all revenue. This region has the highest demand for viral vector CDMO due to the concentration of research and development in the field of progressive genetic therapies. The United States is the leading country in this region and the world in terms of revenue generation through ADVAC viral vector technology services. Besides, the increasing investment by Asia Pacific governments in the development of biotech and disease diagnosis regional research facilities has significantly increased the demand for viral vector products. The demand for viral vector purification rapidly increases as the world’s population grows and healthcare costs rise. Japan is expected to dominate the Asia-Pacific viral vector purification market because it is one of the Asia-Pacific countries that use advanced viral vector purification products for treatments. In addition, the accelerated grant of requests to establish viral vector companies by several private players is found to be the major factor in the regional viral vector market’s rapid growth.
- In May 2022, Merck and its subsidiary MilliporeSigma have finished construction on their second plant in Carlsbad, California. This new US$110 million, 140,000-square-foot facility doubles manufacturing capacity to enable viral vector commercialization and industrialization.
- In January 2021, Thermo Fisher Scientific acquired Groupe Novasep SAS, a viral vector production company. This acquisition is anticipated to enhance capacity and scientific viral vector services at Thermo Fisher throughout North America and abroad.
For More Information @ https://www.insightaceanalytic.com/report/global-viral-vector-purification-market-/1287
Segmentation of Global Viral Vector Purification Market –
By Product Type –
- Prepacked Column
- Filter Plate
By Purification Technique Type –
By Type of Viral Vector Scope –
By Scale of Operation –
By Region –
North America –
- The U.S.
- The U.K.
- Rest of Europe
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America –
- Rest of Latin America
Middle East & Africa –
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Request for ToC/Proposal: https://www.insightaceanalytic.com/request-sample/1287
+1 551 226 6109 Email: firstname.lastname@example.org
PR-Wirein, Financial Content, iCN Internal Distribution, Extended Distribution, Research Newswire, English